Literature DB >> 6086218

In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.

K E Aldridge, C V Sanders, R L Marier.   

Abstract

A broth microdilution checkerboard system was used to determine the activity of cefotaxime (CTX) and desacetylcefotaxime (des-CTX), alone and in combination, against 92 clinical isolates of Bacteroides species. Overall, CTX was only marginally more active than the metabolite. Resistance to both compounds was found among B. fragilis group, B. disiens, B. bivius, and B. capillosus. The combination of CTX with des-CTX resulted in a marked reduction of the MICs greater than or equal to fourfold for 82% of the strains tested. In addition, complete or partial synergy was noted with the combination against 85% of the strains tested. The ratio of CTX to des-CTX at the inhibitory endpoints varied widely, but in 75% of the cases it was 2:1 to 1:2 parts CTX to des-CTX.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086218

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

Review 1.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

2.  Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.

Authors:  G Piédrola; I Galan; A Leyva; M C Maroto
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Cefotaxime stability during in vitro microbiological testing.

Authors:  C R Marchbanks; R L Yost; R L White
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 4.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

5.  The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.

Authors:  H R Devlin; L Boskovski
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.

Authors:  S G Jenkins; J W Lewis
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.